InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

RecruitingLast updated: 8 December 2023

TrAVeRse: This study is evaluating how effective treatment with a combination of targeted therapies is for people with mantle cell lymphoma who have not had prior treatmentA Multicentre, Phase II, Randomised, Open-label Study to Evaluate the Efficacy of Acalabrutinib in Combination With Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma

Clinical summary


Eligible participants will receive treatment with AVR, which consists of three targeted therapies:

  • A Bruton's Tyrosine Kinase-inhibitor called Acalabrutinib;
  • A BCL2 inhibitor called Venetoclax; and
  • an anti-CD20 monoclonal antibody called Rituximab.

All participants are planned to receive 13 cycles of AVR induction. Each cycle is 38 days. During the induction phase, acalabrutinib is administered twice a day orally for a total of 13 cycles starting on Cycle 1, venetoclax is administered once daily orally for a total of 12 cycles starting on Cycle 2, and rituximab is administered intravenously on Day 1 of every cycle, for a total of 12 cycles starting on Cycle 1.

Following this, participants who complete 13 cycles of AVR induction will be centrally tested for minimum residual disease (MRD) status at completion of Cycle 13 and will contibue to receive acalabrutinib twice daily for one full additional cycle (Cycle 14) while awaiting the results of the centralised MRD assessment ande valuation of disease response.

  • Participants whose status is MRD-negative complete response (CR) at the end of Cycle 13 assessments will be randomised in a 1:1 ratio to either receive acalabrutinib or observation starting at Cycle 15. 
  • Participants whose status is MRD-positive CR, PR, or stable disease at the end of Cycle 13 assessments will continue to receive acalabrutinib.

The total duration of the study will be approximately 67 months.


This trial is treating patients with mantle cell lymphoma


Blood Cancers Haematological





Trial Acronym


More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Trial sponsor


Scientific Title

A Multicentre, Phase II, Randomised, Open-label Study to Evaluate the Efficacy of Acalabrutinib in Combination With Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma




  1. Participant must be ≥ 18 years or the legal age of consent in the jurisdiction in which the study is taking place, whichever is greater, at the time of signing the informed consent.

    Type of Participant and Disease Characteristics

  2. Histologically documented MCL based on criteria established by the World Health Organization with documentation of chromosomal translocation t(11;14) (q13;q32) and/or overexpression of cyclin D1 in association with other relevant markers (e.g., CD5, CD19, CD20 or PAX5).
  3. Clinical Stage II, III, or IV by Ann Arbor Classification and requiring treatment in the opinion of the treating clinician.
  4. At least 1 measurable site of disease per Lugano Classification for NHL (Appendix K). The site of disease must be > 1.5 cm in the long axis regardless of short axis measurement or > 1.0 cm in the short axis regardless of long axis measurement, and clearly measurable in 2 perpendicular dimensions, as assessed by diagnostic quality CT (MRI may be used for participants who are either allergic to CT contrast media or have renal insufficiency that per institutional guidelines restricts the use of CT contrast media).

    OR Participant with leukemic non-nodal MCL presentation with mainly splenomegaly and Bone Marrow (BM) or peripheral blood involvement.

  5. Eastern Cooperative Oncology Group PS of 0, 1, or 2 and ECOG PS of 3 if poor PS is due to lymphoma.
  6. Confirmed availability of sufficient FFPE tumour samples for central laboratory genomic profiling, including TP53 and clone identification for MRD testing. Participants with leukemic non-nodal MCL may be enrolled with available BM tissue. For non-nodal leukaemic MCL participants and when nodal or extranodal tissue is not easily accessible and an invasive biopsy will cause a significant risk to the participant, the participant can be enrolled without a tissue biopsy if MCL is confirmed by a BM biopsy and sufficient BM biopsy and aspirate provided for TP53 testing, tumour profiling and clone identification for MRD testing.
  7. Adequate organ and bone marrow function.

Sex and Contraceptive/Barrier Requirements 8 Male and/or female Contraceptive use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

  1. Male participants:

    - Male participants with a female partner of child-bearing potential should use a condom from enrolment, throughout the study until 90 days following the last dose of venetoclax or rituximab, whichever is longer.

    - For non-pregnant potentially childbearing partners, contraception recommendations should also be considered. A male participant must agree to refrain from sperm donation throughout the study until 90 days following the last dose of venetoclax or rituximab, whichever is longer.

  2. Female participants:

    • Women of childbearing potential must have negative serum pregnancy test result prior to the start of study intervention (Cycle 1 Day 1) and agree to abstain from breastfeeding during study participation and at least 12 months after the last drug administration.
    • Female participants of childbearing potential who are sexually active with a nonsterilized male partner must agree to use one highly effective form of birth control from enrolment, throughout the study and at least 2 days after the last dose of acalabrutinib, at least 6 months after the last dose of venetoclax, and at least 12 months after the last dose of rituximab, whichever is longer.

Informed Consent 9 Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol 10 Provision of signed and dated written Optional Genetic Research Information informed consent prior to collection of samples for optional genetic research that supports the Genomic Initiative.


Medical Conditions

  1. Active CNS involvement by lymphoma or leptomeningeal disease
  2. Current or previous active malignancies requiring anticancer therapy except:

    - adequately treated basal cell or squamous cell skin cancer

    - in situ cancer

    - history of cancer with no evidence of recurrence for ≥ 2 years before enrolment

    - local radiotherapy field that does not overlap with sites of MCL disease and the participant had recovered from any toxicity.

    - anti-hormonal therapies are permitted after discussion with the sponsor's medical monitor

  3. Participants for whom the goal of therapy is tumour debulking before ASCT
  4. Any severe or life-threatening illness, medical condition (e.g., uncontrolled hypertension, bleeding diathesis), or organ system dysfunction which, in the investigator' opinion, could compromise the participant safety, interfere with the absorption or metabolism of study intervention (acalabrutinib, rituximab, venetoclax) or put the study outcomes at undue risk
  5. Clinically significant cardiovascular disease such as uncontrolled or untreated symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification, or QTc > 480 msec at screening. Exception: Participants with controlled, asymptomatic atrial fibrillation during screening may enroll.
  6. Any active uncontrolled infection (bacterial, viral, fungal, or other infection), defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment, which in the investigator's opinion makes it undesirable or pose a safety risk for the participant to participate in the study.
  7. HIV infection. As per standard of care, results of HIV serology should be known prior to start of study intervention. In the acute situation, registration may occur without the results of the HIV serology but must be available prior to start of study intervention

    Excluded Participants: Participants with active HIV infection (i.e., with detectable viral load by PCR) are excluded.

    Included Participants: HIV-positive participants receiving anti-retroviral treatment with undetectable viral load by PCR may be enroled following discussion with the participant's HIV physician and the sponsor medical monitor. Potential interactions between anti-retroviral medications and study interventions should be considered.

  8. Serologic status reflecting active hepatitis B or C. As per standard of care, results of hepatitis serology should be known prior to start of study intervention. In the acute situation, enrolment may occur without the results of the hepatitis serology but must be available prior to start of study intervention.

    (a) Participants who are HBsAg positive or hepatitis B PCR positive will not be eligible.Participants who are anti-HBc antibody positive and who are HBsAg negative will need to have a negative PCR result before enrolment. Participants who have protective titres of HBsAb after vaccination will be eligible.

    (b) Participants who are hepatitis C antibody positive and are HCV-PCR positive will not be eligible.

  9. History or ongoing confirmed progressive multifocal leukoencephalopathy.
  10. History of stroke or intracranial haemorrhage within 6 months prior to the first dose of study intervention (Cycle 1 Day 1).
  11. Uncontrolled autoimmune haemolytic anaemia or idiopathic thrombocytopenic purpura.
  12. Active bleeding from a gastrointestinal ulcer, except incidental finding identified on endoscopy that is attributable to MCL
  13. Participants with a known hypersensitivity to acalabrutinib, venetoclax, or rituximab or any of the excipients of the product.
  14. Known allergy to uric acid lowering agents (e.g., xanthine oxidase inhibitors or rasburicase)
  15. Severe prior reactions to monoclonal antibodies
  16. Known glucose-6-phosphate dehydrogenase deficiency
  17. Malabsorption syndrome, disease significantly affecting gastrointestinal function, resection of the stomach, extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass or inability to swallow the formulated product (tablets).
  18. Currently pregnant (confirmed with positive pregnancy test) or breast feeding

    Prior/Concomitant Therapy

  19. Any prior therapies for the treatment of MCL
  20. Requiring continued treatment with a strong CYP3A4 inhibitor/inducer or its use within 7 days prior to the first dose (Cycle 1 Day 1) of acalabrutinib or venetoclax 21 Requiring continued anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon). Exceptions are DOACs rivaroxaban, apixaban, edoxaban and dabigatran

22 Requiring ongoing immunosuppressive therapy, including systemic or enteric corticosteroids except:

  • Topical or inhaled corticosteroids or low-dose oral steroids (≤ 20 mg of prednisone or equivalent per day) as a therapy for comorbid conditions
  • Short courses of glucocorticoids in excess of 20 mg prednisone for no more than 14 days for comorbid conditions.
  • Systemic use of corticosteroids as a prephase to control MCL manifestations

    23 Received major surgery (excluding placement of vascular access or for diagnosis) within 28 days of first dose of study intervention (Cycle 1 Day 1) 24 Receipt of live, attenuated vaccine within 28 days before the first dose of study intervention (Cycle 1 Day 1) (except COVID-19 vaccine).

See Section 6.9, for lists of prohibited (Table 15) and restricted (Table 16) concomitant medications.

Prior/Concurrent Clinical Study Experience 25 Concurrent participation in another clinical study

Other Exclusions 26 Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).

27 Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.

28 Previous enrolment in the present study.


  • You are able to swallow medication by mouth.
  • You have been diagnosed with cancer, but have not received any treatment.


  • You have been diagnosed with a prior or secondary type of cancer.
  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support


Cancer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Cancer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Learn more


Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more


Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more

Victorian Cancer Registry Victorian Government

The Victorian Cancer Trials Link is supported by the Victorian Government through the Victorian Cancer Agency.


Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.